Hawkins, Inc. (HWKN) 10-K Summary
Business Context and Reporting Period
Company: Hawkins, Inc.
Filing Type: Form 10-K (Annual Report)
Fiscal Year Ended: April 1, 2007
Business Overview: Hawkins, Inc. is a distributor, blender, and formulator of bulk and specialty chemicals operating in three segments: Water Treatment, Industrial, and Pharmaceutical. The company operates primarily in the United States, with significant facilities in Minnesota and distribution centers across the Midwest.
Key Financial Metrics
| Metric | Fiscal 2007 | Fiscal 2006 | Change |
|---|---|---|---|
| Sales | $160,405,080 | $143,331,250 | +11.9% |
| Gross Margin | $37,236,977 (23.2%) | $33,219,142 (23.2%) | 0.0% |
| Net Income | $8,068,883 | $8,886,153 | -9.2% |
| Earnings Per Share (Basic/Diluted) | $0.79 | $0.87 | -9.2% |
| Cash Flow from Operations | $8,729,475 | $9,457,722 | -7.7% |
| Total Assets | $101,268,594 | $94,056,734 | +7.7% |
| Cash & Cash Equivalents | $11,592,939 | $6,330,004 | +83.1% |
| Dividends Declared Per Share | $0.44 | $0.40 | +10.0% |
Material Changes vs. Prior Period
- Sales Growth: Total sales increased by $17.1 million (11.9%). The Industrial segment grew 13.3% and the Water Treatment segment grew 15.2%, driven by volume increases and price adjustments. Conversely, the Pharmaceutical segment declined 15.2% due to FDA restrictions on certain products.
- Profitability Decline: Despite higher sales, Net Income decreased by $817,000 (9.2%). This was primarily due to a $4.5 million increase in Selling, General, and Administrative (SG&A) expenses, largely attributed to the implementation of a new Enterprise Resource Planning (ERP) system (approx. $1.8 million in consulting fees).
- Segment Performance: The Pharmaceutical segment reported an operating loss of $234,819 in 2007, compared to an operating income of $1.6 million in 2006 (which included a $1.06 million litigation settlement gain). The Industrial and Water Treatment segments remained profitable.
- Liquidity: Cash and cash equivalents increased significantly to $11.6 million, aided by the repayment of three notes receivable totaling approximately $2.3 million.
Outlook, Risks, and Unusual Items
- ERP Implementation Risks: The company implemented a new ERP system in October 2006. While internal controls were deemed effective as of April 1, 2007, the transition caused delays, extra costs, and required manual controls. Management expects consulting costs to decrease in fiscal 2008.
- FDA Regulatory Issues: The Pharmaceutical segment faces ongoing restrictions from the FDA regarding packaging validation and expiration dating. Approximately $45,000 of inventory is currently unsellable. Management does not expect a material impact on overall company results but notes uncertainty for the segment.
- Acquisition: On May 15, 2007 (post-fiscal year end), the company signed an agreement to acquire Trumark, Inc. for approximately $6.0 million. The acquired business produces antimicrobial products for the food industry and will be integrated into the Industrial segment.
- Seasonality: The Water Treatment segment is seasonal, with higher sales typically occurring from April to September.
- Commodity Price Volatility: The company is exposed to cyclical commodity chemical prices (e.g., caustic soda). While they attempt to pass costs to customers, delays in doing so can compress margins.
Investor Verification Checklist
- ERP System Stability: Verify if the transition to the new ERP system has stabilized and if SG&A expenses are trending downward as projected for fiscal 2008.
- FDA Resolution: Monitor the status of the FDA warning letter and the timeline for resuming full sales of restricted Pharmaceutical products.
- Trumark Integration: Assess the financial impact and integration progress of the Trumark, Inc. acquisition in the upcoming fiscal quarters.
- Customer Concentration: Confirm that the top five customers (representing approx. 10% of sales) remain stable, as their loss could materially affect operations.
- Lease Renewals: Review the status of land leases for the three main terminals, which expire between 2018 and 2029, to ensure no disruption to bulk chemical storage.